Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 8 |
| List of Tables | 8 | 2 |
| List of Figures | 10 | 3 |
| Introduction | 13 | 1 |
| Clinical Trials Endpoints in Respiratory Diseases - An Overview | 14 | 2 |
| Introduction | 14 | 1 |
| Types of Endpoints | 14 | 1 |
| Primary Endpoints | 14 | 1 |
| Secondary Endpoints | 14 | 1 |
| Surrogate Endpoints | 15 | 1 |
| Endpoints - Clinical Trials in Asthma - Marketed and Pipeline Products Assessment | 16 | 60 |
| Introduction | 16 | 4 |
| Primary Endpoints Used in Asthma Clinical Trials | 20 | 1 |
| Pulmonary Function Tests: | 20 | 1 |
| Vital Signs and Physical Activity | 20 | 1 |
| Biomarkers | 20 | 1 |
| Serious Adverse Events | 20 | 1 |
| Secondary Endpoints Used in Asthma Clinical Trials | 21 | 1 |
| Pharmacokinetics and Pharmacodynamics | 21 | 1 |
| Quality of Life Scores | 21 | 1 |
| Clinical Laboratory Tests Biochemistry and Serum Hematology | 21 | 1 |
| Use of Rescue Medication | 21 | 1 |
| Asthma Therapeutics Major Marketed Drugs | 21 | 1 |
| Singulair (Montekeulast Sodium) | 21 | 1 |
| Overview | 21 | 1 |
| Efficacy | 21 | 1 |
| Safety | 21 | 1 |
| Clinical Study Details | 22 | 1 |
| Accolate Accoleit, Vanticon (Zafirlukast) | 22 | 1 |
| Overview | 22 | 1 |
| Efficacy | 22 | 1 |
| Safety | 23 | 1 |
| Clinical Study Details | 23 | 1 |
| Zyflo (Zileuton) | 23 | 1 |
| Overview | 23 | 1 |
| Efficacy | 23 | 1 |
| Safety | 23 | 1 |
| Clinical Study Details | 24 | 1 |
| Foradil (Formoterol Fumarate Inhalation Powder) | 24 | 1 |
| Overview | 24 | 1 |
| Efficacy | 24 | 1 |
| Safety | 24 | 1 |
| Clinical Study Details | 25 | 1 |
| Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) | 25 | 1 |
| Overview | 25 | 1 |
| Efficacy | 26 | 1 |
| Safety | 26 | 1 |
| Clinical Study Details | 26 | 1 |
| Xolair (Omalizumab) | 27 | 1 |
| Overview | 27 | 1 |
| Efficacy | 27 | 1 |
| Safety | 27 | 1 |
| Clinical Study Details | 27 | 1 |
| Serevent Diskus (Salmaterol Xinafoate Inhalation Powder) | 28 | 1 |
| Overview | 28 | 1 |
| Efficacy | 28 | 1 |
| Safety | 29 | 1 |
| Clinical Study Details | 29 | 1 |
| Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder) | 29 | 1 |
| Overview | 29 | 1 |
| Efficacy | 29 | 1 |
| Safety | 29 | 1 |
| Clinical Study Details | 30 | 1 |
| Asthma Therapeutics Promising Drugs under Clinical Development | 30 | 1 |
| Daxas (Roflumilast) (Daxas, APTA 2217, B9302-107, BY 217, BYK 20869) | 30 | 1 |
| Overview | 30 | 1 |
| Efficacy | 30 | 1 |
| Safety | 30 | 1 |
| Clinical Study Details | 31 | 1 |
| Phase III Clinical Trial Analysis | 31 | 1 |
| Completed Trial Analysis | 31 | 4 |
| Active Trial Analysis | 35 | 4 |
| Terminated Trial Analysis | 39 | 2 |
| Phase II Clinical Trial Analysis | 41 | 1 |
| Completed Trial Analysis | 41 | 4 |
| Active Trial Analysis | 45 | 4 |
| Terminated Trial Analysis | 49 | 27 |
| Endpoints - Clinical Trials in Chronic Obstructive Pulmonary Disorder - Marketed and Pipeline Products Assessment | 76 | 49 |
| Introduction | 76 | 4 |
| Primary Endpoints Used in COPD Clinical Trials | 80 | 1 |
| Pulmonary Function Tests | 80 | 1 |
| Baseline Dyspnea Index and Borg-Dyspnea Score | 80 | 1 |
| Rate of Exacerbations | 80 | 1 |
| Induced Sputum Analysis | 80 | 1 |
| Biomarkers of COPD | 80 | 1 |
| Secondary Endpoints Used in COPD Clinical Trials | 80 | 1 |
| Exercise Endurance Time | 80 | 1 |
| Serum Hematology | 80 | 1 |
| Six Minute Walk Distance | 80 | 1 |
| Time to First Exacerbation | 81 | 1 |
| COPD Therapeutics Major Marketed Drugs | 81 | 1 |
| Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) | 81 | 1 |
| Overview | 81 | 1 |
| Efficacy | 81 | 1 |
| Safety | 81 | 1 |
| Clinical Study Details | 81 | 1 |
| Brovana (Arformoterol) | 82 | 1 |
| Overview | 82 | 1 |
| Efficacy | 82 | 1 |
| Safety | 82 | 1 |
| Clinical Study Details | 82 | 1 |
| Foradil Aerolizer (Formoterol Fumarate Inhalation Powder) | 83 | 1 |
| Overview | 83 | 1 |
| Efficacy | 83 | 1 |
| Safety | 83 | 1 |
| Clinical Study Details | 83 | 1 |
| Symbicort (Budesonide/Formoterol Fumarate Dihydrate) | 84 | 1 |
| Overview | 84 | 1 |
| Efficacy | 84 | 1 |
| Safety | 84 | 1 |
| Clinical Study Details | 84 | 1 |
| Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder) | 85 | 1 |
| Overview | 85 | 1 |
| Efficacy | 85 | 1 |
| Safety | 85 | 1 |
| Clinical Study Details | 85 | 2 |
| Daxas (roflumilast) | 87 | 1 |
| Overview | 87 | 1 |
| Efficacy | 87 | 1 |
| Safety | 87 | 1 |
| Clinical Study Details | 87 | 1 |
| COPD Therapeutics Promising Drugs Under Clinical Development | 88 | 1 |
| Aclidinium Bromide | 88 | 1 |
| Overview | 88 | 1 |
| Efficacy | 88 | 1 |
| Safety | 88 | 1 |
| Clinical Study Details | 88 | 1 |
| NVA237 (Glycopyrronium Bromide) | 89 | 1 |
| Overview | 89 | 1 |
| Efficacy | 89 | 1 |
| Safety | 89 | 1 |
| Clinical Study Details | 89 | 1 |
| Dulera | 89 | 1 |
| Overview | 89 | 1 |
| Clinical Study Details | 90 | 1 |
| Phase III Clinical Trial Analysis | 90 | 1 |
| Completed Trial Analysis | 90 | 4 |
| Active Trials Analysis | 94 | 4 |
| Terminated Trial Analysis | 98 | 2 |
| Phase II Clinical Trial Analysis | 100 | 1 |
| Completed Trial Analysis | 100 | 4 |
| Active Trial Analysis | 104 | 3 |
| Terminated Trial Analysis | 107 | 18 |
| Endpoints - Clinical Trials in Cystic Fibrosis - Marketed and Pipeline Products Assessment | 125 | 31 |
| Introduction | 125 | 4 |
| Primary Endpoints Used in Cystic Fibrosis Clinical Trials | 129 | 1 |
| Coefficient of Fat Absorption | 129 | 1 |
| Lung Microbiology | 129 | 1 |
| Biomarkers | 129 | 1 |
| Secondary Endpoints Used in Cystic Fibrosis Clinical Trials | 129 | 1 |
| Nasal Potential Difference | 129 | 1 |
| Sweat Chloride Concentration | 129 | 1 |
| Cystic Fibrosis Therapeutics Major Marketed Drugs | 129 | 1 |
| Tobi (Tobramycin Inhalation Solution) | 129 | 1 |
| Overview | 129 | 1 |
| Efficacy | 130 | 1 |
| Safety | 130 | 1 |
| Clinical Study Details | 130 | 1 |
| Pulmozyme (Dornase Alfa) | 130 | 1 |
| Overview | 130 | 1 |
| Efficacy | 131 | 1 |
| Safety | 131 | 1 |
| Clinical Study Details | 131 | 1 |
| Cayston (aztreonam for Inhalation Solution) | 131 | 1 |
| Overview | 131 | 1 |
| Efficacy | 131 | 1 |
| Safety | 132 | 1 |
| Clinical Study Details | 132 | 1 |
| Colistimethate sodium (Colistin, Colomycin Injection, Promixin, Coly-Mycin M) | 132 | 1 |
| Overview | 132 | 1 |
| Efficacy | 132 | 1 |
| Safety | 133 | 1 |
| Cystic Fibrosis Promising Drugs Under Clinical Development | 133 | 1 |
| Denufosol Tetrasodium Inhalation Solution (INS37217) | 133 | 1 |
| Overview | 133 | 1 |
| Efficacy | 133 | 1 |
| Safety | 133 | 1 |
| Clinical Study Details | 133 | 1 |
| VX-770 | 134 | 1 |
| Overview | 134 | 1 |
| Efficacy | 134 | 1 |
| Safety | 134 | 1 |
| Clinical Study Details | 134 | 1 |
| Bronchitol | 134 | 1 |
| Overview | 134 | 1 |
| Efficacy | 134 | 1 |
| Safety | 135 | 1 |
| Clinical Study Details | 135 | 1 |
| Ataluren (PTC-124) | 135 | 1 |
| Overview | 135 | 1 |
| Efficacy | 135 | 1 |
| Safety | 135 | 1 |
| Clinical Study Details | 135 | 1 |
| Phase III Clinical Trial Analysis | 136 | 1 |
| Completed Trial Analysis | 136 | 2 |
| Active Trial Analysis | 138 | 3 |
| Terminated Trial Analysis | 141 | 2 |
| Phase II Clinical Trial Analysis | 143 | 1 |
| Completed Trial Analysis | 143 | 3 |
| Active Trial Analysis | 146 | 3 |
| Terminated Trial Analysis | 149 | 7 |
| Endpoints - Clinical Trials in Pulmonary Arterial Hypertension - Marketed and Pipeline Products Assessment | 156 | 31 |
| Introduction | 156 | 1 |
| Classification of Pulmonary Hypertension | 156 | 5 |
| Primary Endpoints Used in Pulmonary Hypertension Trials | 161 | 1 |
| Cardiopulmonary Hemodynamic Test | 161 | 1 |
| Six Minutes Walking Distance | 161 | 1 |
| Biomarkers | 161 | 1 |
| Secondary Endpoints Used in Pulmonary Hypertension Trials | 161 | 1 |
| Time to Clinical Worsening | 161 | 1 |
| SF-36 Health Survey | 161 | 1 |
| Pulmonary Arterial Hypertension Major Marketed Drugs | 161 | 1 |
| Tracleer | 161 | 1 |
| Overview | 161 | 1 |
| Efficacy | 161 | 1 |
| Safety Profile | 162 | 1 |
| Clinical Study Details | 162 | 1 |
| Remodulin | 162 | 1 |
| Overview | 162 | 1 |
| Efficacy | 162 | 1 |
| Safety | 162 | 1 |
| Clinical Study Details | 163 | 1 |
| Revatio | 163 | 1 |
| Overview | 163 | 1 |
| Efficacy | 163 | 1 |
| Safety | 163 | 1 |
| Clinical Study Details | 163 | 1 |
| Ventavis | 164 | 1 |
| Overview | 164 | 1 |
| Safety | 164 | 1 |
| Clinical Study Details | 164 | 1 |
| Letairis | 165 | 1 |
| Overview | 165 | 1 |
| Efficacy | 165 | 1 |
| Safety | 165 | 1 |
| Clinical Study Details | 165 | 1 |
| Adcirca | 166 | 1 |
| Overview | 166 | 1 |
| Efficacy | 166 | 1 |
| Safety | 166 | 1 |
| Clinical Study Details | 166 | 1 |
| Pulmonary Arterial Hypertension Promising Drugs under Clinical Development | 167 | 1 |
| ACT-064992 | 167 | 1 |
| Overview | 167 | 1 |
| Efficacy | 167 | 1 |
| Safety | 167 | 1 |
| Clinical Study Details | 167 | 1 |
| Oral Treprostinil | 168 | 1 |
| Overview | 168 | 1 |
| Efficacy | 168 | 1 |